<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-55" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atorvastatin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McIver</surname>
            <given-names>Lindsey A.</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddique</surname>
            <given-names>Momin S.</given-names>
          </name>
          <aff>SIU</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lindsey McIver declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Momin Siddique declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>9</month>
          <year>2020</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-55.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">HMG-CoA reductase inhibitors (statins) are lipid-lowering medications used in the primary, secondary, and tertiary prevention of coronary heart disease. Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. By preventing the conversion of HMG-CoA to mevalonate, statin medications decrease cholesterol production in the liver. Atorvastatin also increases the number of LDL receptors on the surface of hepatic cells. This activity reviews the indications, contraindications, and mechanism of action of atorvastatin to manage coronary heart disease and familial dyslipidemias, covering the indications, contraindications, activity, adverse events, and other key elements of atorvastatin therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for atorvastatin therapy.</p></list-item><list-item><p>Identify potential adverse events when using therapy with atorvastatin.</p></list-item><list-item><p>Outline the appropriate follow-up and monitoring of lipid-lowering therapy with atorvastatin.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to enhance patient adherence to atorvastatin in treating coronary artery disease and hyperlipidemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=55&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=55">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-55.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Combined with dietary modifications, atorvastatin is FDA-approved to prevent cardiovascular events in patients with cardiac risk factors and abnormal lipid profiles.<xref ref-type="bibr" rid="article-55.r1">[1]</xref></p>
        <p>
<bold>Secondary Prevention</bold>
</p>
        <p>For patients without coronary heart disease but with multiple risk factors, the FDA has approved atorvastatin to reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina.</p>
        <p>For patients diagnosed with type 2 diabetes mellitus without coronary heart disease but with multiple risk factors, atorvastatin has FDA approval to reduce the risk of myocardial infarction and stroke.&#x000a0;&#x000a0;</p>
        <p>
<bold>Tertiary Prevention</bold>
</p>
        <p>For patients with coronary heart disease, atorvastatin has received approval as a therapy to reduce the risk of nonfatal myocardial infarction, fatal and nonfatal stroke, revascularization procedures, hospitalizations for congestive heart failure, and angina.&#x000a0;</p>
        <p>Atorvastatin has FDA approval for the treatment of the following dyslipidemias:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia</p>
          </list-item>
          <list-item>
            <p>Hypertriglyceridemia</p>
          </list-item>
          <list-item>
            <p>Primary dysbetalipoproteinemia</p>
          </list-item>
          <list-item>
            <p>Homozygous familial hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Pediatric patients with heterozygous familial hypercholesterolemia (after failing dietary modifications)</p>
          </list-item>
        </list>
        <p>Atorvastatin has not been studied in Fredrickson Type I and V dyslipidemias.</p>
      </sec>
      <sec id="article-55.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.<xref ref-type="bibr" rid="article-55.r2">[2]</xref>&#x000a0;Statin medications decrease cholesterol production in the liver by preventing HMG-CoA conversion to mevalonate. Atorvastatin also increases the number of LDL receptors on the surface of hepatic cells.&#x000a0;</p>
        <p>In patients with homozygous or heterozygous familial hypercholesterolemia, mixed dyslipidemia, isolated hypertriglyceridemia, or nonfamilial hypercholesterolemia, atorvastatin has been shown to reduce total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), very-low-density lipoprotein (VLDL-C) and triglycerides (TGs) while increasing high-density lipoprotein cholesterol (HDL-C).&#x000a0;</p>
        <p>In patients with dysbetalipoproteinemia, atorvastatin has been shown to decrease intermediate-density lipoprotein (IDL-C).&#x000a0;&#x000a0;&#x000a0;</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The pharmacokinetic attributes of atorvastatin are covered below.<xref ref-type="bibr" rid="article-55.r3">[3]</xref><bold>&#x000a0;</bold></p>
        <p><bold>Absorption</bold>&#x000a0;</p>
        <p>Atorvastatin is rapidly absorbed after oral administration with a peak plasma concentration at 1 to 2 hours. The bioavailability is low at 14% due to extensive first-pass metabolism.</p>
        <p>
<bold>Distribution</bold>
</p>
        <p>Atorvastatin is highly plasma protein bound (over 98%) and has a volume of distribution of about 380 liters.&#x000a0;</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Atorvastatin is metabolized by cytochrome P450 3A4 (CYP3A4) to active ortho- and para-hydroxylated metabolites.&#x000a0;</p>
        <p>
<bold>Excretion</bold>
</p>
        <p>Atorvastatin and its metabolites get eliminated in bile. Atorvastatin is not known to go through enterohepatic recirculation. The half-life of atorvastatin is about 14 hours, while its active metabolites have a half-life of about 20 to 30 hours.&#x000a0;</p>
      </sec>
      <sec id="article-55.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Atorvastatin is available as atorvastatin calcium tablets in strengths of 10, 20, 40, and 80 mg.&#x000a0;&#x000a0;</p>
        <p>This medication can be administered with or without food and should be taken at the same time every day. It is generally recommended to administer statins at bedtime since endogenous cholesterol synthesis is cyclical, with the highest production levels during fasting as at night. However, the longer half-life of atorvastatin compared to other shorter half-life statins (e.g., lovastatin, fluvastatin, and simvastatin) offers greater flexibility regarding dosing times.</p>
        <p>
<bold>Adult Dosing&#x000a0;</bold>
</p>
        <p>The dosing of atorvastatin can have its basis in LDL-C lowering ability (intensity), or doses are titratable to specific lipid goals.&#x000a0;</p>
        <p>The American College of Cardiology/American Heart Association Guidelines recommends either moderate intensity (atorvastatin 10 to 20 mg) or high intensity (atorvastatin 40 to 80 mg) therapy, depending on&#x000a0;the statin benefit group to which a patient belongs. Moderate-intensity statins should lower LDL-C by about 30 to 50%, while high-intensity statins should lower LDL-C by over 50%.<xref ref-type="bibr" rid="article-55.r4">[4]</xref></p>
        <p>The National Lipid Association and the American Association of Clinical Endocrinologists recommend utilizing statin therapy to reach specific lipid goals based on&#x000a0;atherosclerotic cardiovascular disease&#x000a0;risk.<xref ref-type="bibr" rid="article-55.r5">[5]</xref><xref ref-type="bibr" rid="article-55.r6">[6]</xref></p>
        <p>
<bold>Pediatrics&#x000a0;</bold>
</p>
        <p>Doses above 20 mg do not have study data for pediatric patients with heterozygous familial hypercholesterolemia. Doses up to 80 mg have been used in a limited number of pediatric patients with familial hypercholesterolemia. Studies have not evaluated atorvastatin use in pre-pubescent patients or those under ten years old.&#x000a0;</p>
        <p>
<bold>Geriatrics</bold>
</p>
        <p>Patients&#x000a0;older than 65 may have higher plasma concentrations of atorvastatin than young adults. Older patients may be at increased risk of statin-induced myopathies.&#x000a0;</p>
        <p>
<bold>Renal Impairment&#x000a0;</bold>
</p>
        <p>Atorvastatin and its metabolites do not undergo renal elimination, so no dose adjustments are required with reduced renal function. Hemodialysis will not likely remove atorvastatin due to plasma protein binding.&#x000a0;</p>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <p>Increased plasma concentrations of atorvastatin have occurred in patients with chronic alcoholic liver disease. Drug exposure is four times higher in patients with Child-Pugh Class A and 11x higher in patients with Child-Pugh Class B. Atorvastatin is contraindicated in patients with active liver disease.<xref ref-type="bibr" rid="article-55.r7">[7]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Using atorvastatin with potent CYP3A4 inhibitors can lead to increased plasma concentrations, which may enhance adverse events, including myopathy. OATP1B1 inhibitors can increase the bioavailability of atorvastatin.<xref ref-type="bibr" rid="article-55.r9">[9]</xref></p>
        <p>CYP3A4 inducers may cause decreased plasma concentrations of atorvastatin.&#x000a0;</p>
        <p>Patients taking digoxin should undergo monitoring when starting atorvastatin as plasma concentrations of digoxin may increase.</p>
        <p>Atorvastatin may also increase drug&#x000a0;concentrations of norethindrone and ethinyl estradiol.<xref ref-type="bibr" rid="article-55.r8">[8]</xref><bold>&#x000a0;</bold></p>
      </sec>
      <sec id="article-55.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects for patients taking atorvastatin include arthralgia, dyspepsia, diarrhea, nausea, nasopharyngitis, insomnia, urinary tract infection, and pain in the extremities.</p>
        <p>Myopathies have occurred in patients taking atorvastatin, including muscle aches, muscle tenderness, or muscle weakness, with elevated creatine phosphokinase greater than ten times the upper limit of normal. Rhabdomyolysis has been reported in patients using atorvastatin.<xref ref-type="bibr" rid="article-55.r10">[10]</xref> Patients with impaired renal function may be at increased risk of developing rhabdomyolysis. Using atorvastatin in combination with other medications that increase atorvastatin plasma concentrations increases the risk for myopathies and rhabdomyolysis.<xref ref-type="bibr" rid="article-55.r11">[11]</xref>&#x000a0;Management of statin-induced myopathies includes temporarily holding therapy, switching to an alternative statin, or reducing the dose.&#x000a0;</p>
        <p>Some data suggest that statins may increase the risk of developing diabetes mellitus. In 2012, the FDA added safety label changes to statin safety labeling, indicating that they have been shown to increase glycosylated hemoglobin and fasting serum glucose.<xref ref-type="bibr" rid="article-55.r12">[12]</xref>&#x000a0;The ACC/AHA guidelines group and other experts state that the risk-reducing benefits of statin therapy outweigh the generally mild rise in serum glucose levels or new-onset diabetes.<xref ref-type="bibr" rid="article-55.r13">[13]</xref>&#x000a0;Clinicians are encouraged to use this opportunity to discuss healthy lifestyle measures with their patients, including weight loss, engaging in an exercise program, and consuming a healthy diet.</p>
        <p>Atorvastatin can cause liver function test abnormalities.<xref ref-type="bibr" rid="article-55.r7">[7]</xref> If patients develop serum transaminases over&#x000a0;3 times the upper limit of normal, plasma concentrations require more frequent monitoring until normalized or atorvastatin therapy should&#x000a0;undergo dose reduction or be discontinued.&#x000a0;</p>
      </sec>
      <sec id="article-55.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Atorvastatin contraindications include patients with hypersensitivity to any of its components.</p>
        <p>While atorvastatin contraindications also include patients with active liver disease, the benefits of lipid-lowering therapy in chronic liver diseases, such as non-alcoholic fatty liver disease and hepatitis, likely outweigh the possible risks.<xref ref-type="bibr" rid="article-55.r14">[14]</xref></p>
        <p>Atorvastatin is contraindicated during pregnancy or in female patients who may become pregnant. All female patients of childbearing age should receive counseling on the potential risks to a fetus should they become pregnant while on atorvastatin. This risk is most pronounced in the first trimester, so current guidelines recommend ceasing statin therapy for at least&#x000a0;3 months before becoming pregnant. The patient should discontinue this medication immediately if they become pregnant. However, a recent meta-analysis has called this restriction into question; more research will be necessary to accurately assess the risk-benefit ratio of using statins during pregnancy.<xref ref-type="bibr" rid="article-55.r15">[15]</xref></p>
        <p>Female patients should also avoid atorvastatin if they are nursing. If patients require atorvastatin therapy, they should receive direction to discontinue breastfeeding.&#x000a0;</p>
      </sec>
      <sec id="article-55.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients starting atorvastatin should have liver function tests and a lipid panel performed at baseline, with a repeat lipid panel after six weeks of therapy. Liver function tests should be repeated as clinically indicated. Once the patient is stable, lipids can be checked every 6 to 12 months. It may also be prudent to periodically monitor serum blood glucose levels in patients with diabetes or at risk for diabetes.</p>
      </sec>
      <sec id="article-55.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are no antidotes available for&#x000a0;atorvastatin overdose. Patients should be monitored for adverse events and provided with supportive care.&#x000a0;</p>
      </sec>
      <sec id="article-55.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The success of statins in lowering lipids or preventing cardiovascular events depends on the patient's medication adherence. Some barriers to successful statin therapy include experiencing adverse effects, lack of understanding of the importance of statin therapy, and cost; these factors may prevent patients from taking these medications as prescribed. It is also crucial for the interprofessional team to emphasize the importance of lifestyle modification in treating hyperlipidemia. This includes eating a proper, healthy diet, adding exercise or activity several times a week, and losing weight if necessary. A dietician or nutritionist may be a valuable addition to the healthcare team to help guide patients through the necessary dietary changes.</p>
        <p>All interprofessional healthcare team members can help identify barriers to adherence. Additional education and counseling around patient concerns and medication benefits may help improve compliance.<xref ref-type="bibr" rid="article-55.r16">[16]</xref>&#x000a0; Healthcare team members must communicate across disciplinary lines to optimize therapy. Clinicians make the initial assessment and prescribe statin therapy. Nurses can counsel the patients on taking their medication, check for adherence to treatment and adverse effects on subsequent visits, and report back to the prescriber. Pharmacists can guide the patients on optimal dosing (eg, take the drug at bedtime) and check for drug-drug interactions, reporting to the prescriber or nurse. Pharmacists can also inquire about the most common adverse effects since they will see the patient more frequently and let nursing know so it can be relayed to the prescriber as well; open communication between all interprofessional team members combined with accurate record keeping is crucial to optimal care and improved patient outcomes. These are a few examples of how interprofessional team interaction can optimize atorvastatin therapy.&#x000a0;</p>
      </sec>
      <sec id="article-55.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=55&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=55">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/55/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=55">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-55.s11">
        <title>References</title>
        <ref id="article-55.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raddino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Della Pina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gorga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caretta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Madureri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dei Cas</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].</article-title>
            <source>G Ital Cardiol (Rome)</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10 Suppl 1</issue>
            <fpage>78S</fpage>
            <page-range>78S-83S</page-range>
            <pub-id pub-id-type="pmid">21416832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dagli-Hernandez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lauschke</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Genvigir</surname>
                <given-names>FDV</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>TDC</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>RDC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.</article-title>
            <source>Pharmacol Rep</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-66</page-range>
            <pub-id pub-id-type="pmid">34403130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karvaly</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Kar&#x000e1;di</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vincze</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Neely</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Trojn&#x000e1;r</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Proh&#x000e1;szka</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Imreh</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>V&#x000e1;s&#x000e1;rhelyi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zs&#x000e1;ry</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>e00856</fpage>
            <pub-id pub-id-type="pmid">34478238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bairey Merz</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Eckel</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shero</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Eddleman</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Jarrett</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>LaBresh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nevo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wnek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tomaselli</surname>
                <given-names>GF</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Jun</month>
            <day>24</day>
            <volume>129</volume>
            <issue>25 Suppl 2</issue>
            <fpage>S1</fpage>
            <page-range>S1-45</page-range>
            <pub-id pub-id-type="pmid">24222016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bays</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>WV</given-names>
              </name>
            </person-group>
            <article-title>National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.</article-title>
            <source>J Clin Lipidol</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-69</page-range>
            <pub-id pub-id-type="pmid">25911072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jellinger</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Handelsman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rosenblit</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Bloomgarden</surname>
                <given-names>ZT</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Grunberger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guerin</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>DSH</given-names>
              </name>
              <name>
                <surname>Mechanick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Pessah-Pollack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wyne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.</article-title>
            <source>Endocr Pract</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>Suppl 2</issue>
            <fpage>1</fpage>
            <page-range>1-87</page-range>
            <pub-id pub-id-type="pmid">28437620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filppula</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hirvensalo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parviainen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ivaska</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nnberg</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Viinam&#x000e4;ki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kurkela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niemi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>49</volume>
            <issue>8</issue>
            <fpage>658</fpage>
            <page-range>658-667</page-range>
            <pub-id pub-id-type="pmid">34045219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirota</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ieiri</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>809</fpage>
            <page-range>809-822</page-range>
            <pub-id pub-id-type="pmid">32729746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bo&#x0017e;ina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ganoci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Simi&#x0010d;evi&#x00107;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gvozdanovi&#x00107;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Domjanovi&#x00107;</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Fistrek Prli&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kri&#x0017e;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bori&#x00107; Bilu&#x00161;i&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laganovi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bo&#x0017e;ina</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.</article-title>
            <source>Arh Hig Rada Toksikol</source>
            <year>2021</year>
            <month>Jun</month>
            <day>28</day>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>114</fpage>
            <page-range>114-128</page-range>
            <pub-id pub-id-type="pmid">34187111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Srai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudrangi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Statin-Induced Autoimmune Myopathy.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Feb</month>
            <day>26</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>e13576</fpage>
            <pub-id pub-id-type="pmid">33815984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayatilaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rijal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Statin-Induced Autoimmune Necrotizing Myopathy.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>12</volume>
            <fpage>21501327211028714</fpage>
            <pub-id pub-id-type="pmid">34219515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chogtu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Magazine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bairy</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Statin use and risk of diabetes mellitus.</article-title>
            <source>World J Diabetes</source>
            <year>2015</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-7</page-range>
            <pub-id pub-id-type="pmid">25789118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sekhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gourishetti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Kinra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shenoy</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kishore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nandakumar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Role of Statins in New-onset Diabetes Mellitus: The Underlying Cause, Mechanisms Involved, and Strategies to Combat.</article-title>
            <source>Curr Drug Targets</source>
            <year>2021</year>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1121</fpage>
            <page-range>1121-1128</page-range>
            <pub-id pub-id-type="pmid">33494673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tandra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vuppalanchi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Use of statins in patients with liver disease.</article-title>
            <source>Curr Treat Options Cardiovasc Med</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <page-range>272-8</page-range>
            <pub-id pub-id-type="pmid">19627660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zarek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The fetal safety of statins: a systematic review and meta-analysis.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>506</fpage>
            <page-range>506-509</page-range>
            <pub-id pub-id-type="pmid">24927189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-55.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maningat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Breslow</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>How do we improve patient compliance and adherence to long-term statin therapy?</article-title>
            <source>Curr Atheroscler Rep</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>291</fpage>
            <pub-id pub-id-type="pmid">23225173</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
